General Information of DTT (ID: TTJQOD7)

DTT Name 5-HT 2A receptor (HTR2A) DTT Info
Gene Name HTR2A

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Patented Agent(s)
Investigative Drug(s)
9 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [1]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [2]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [3]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [4]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [5]
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [6]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [7]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [8]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Approved Drug(s)
23 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Blonanserin DM36C17 Schizophrenia 6A20 Phase 3 [10]
ITI-007 DMUQ1DO Depression 6A70-6A7Z Phase 3 [11]
M100907 DM7ZFBA Sleep-wake disorder 7A00-7B2Z Phase 3 [12]
MIN-101 DMCJY35 Schizophrenia 6A20 Phase 3 [13]
SR46349B DM1ODMR Primary insomnia 7A00 Phase 3 [14]
TNX-102 DMO1234 Fibromyalgia MG30.01 Phase 3 [15]
TRYPTAMINE DMAFPHB N. A. N. A. Phase 3 [16]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [17]
BVT.28949 DM8CWL0 Glaucoma/ocular hypertension 9C61 Phase 2 [18]
FKW00GA DMPXH7N Social phobia 6B04 Phase 2 [19]
NELOTANSERIN DM4LKFO Lewy body dementia 6D82 Phase 2 [20]
Nuplazid DMOJA5G Alzheimer disease 8A20 Phase 2 [21]
Ocaperidone DMP6B59 Idiopathic pulmonary fibrosis CB03.4 Phase 2 [13]
PRUVANSERIN DMM7F1E Sleep-wake disorder 7A00-7B2Z Phase 2 [22]
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [19]
SYN120 DMDF7XB Parkinson disease 8A00.0 Phase 2 [23]
1192U90 DM5IPHE Psychotic disorder 6A20-6A25 Phase 1 [10]
Abaperidone DMYFB10 Schizophrenia 6A20 Phase 1 [24]
ATI-9242 DM6GKMU Schizophrenia 6A20 Phase 1 [25]
DSP-1200 DM4WSHG Depression 6A70-6A7Z Phase 1 [19]
SKL-10406 DMW64UZ Major depressive disorder 6A70.3 Phase 1 [26]
Temanogrel DM7Q4EX Cardiovascular disease BA00-BE2Z Phase 1 [27]
YKP-1358 DMKHVNE Schizoaffective disorder 6A21 Phase 1 [28]
------------------------------------------------------------------------------------
⏷ Show the Full List of 23 Clinical Trial Drug(s)
34 Patented Agent(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
3-phenyl pyrazole derivative 1 DM3VB6G N. A. N. A. Patented [29]
Aryl piperazine derivative 1 DM9DJGU N. A. N. A. Patented [30]
Aryl piperazine derivative 6 DMZ3DS5 N. A. N. A. Patented [30]
Aryl piperazine derivative 9 DMLKNWF N. A. N. A. Patented [29]
Benzoyl-piperidine derivative 1 DMJBOL0 N. A. N. A. Patented [29]
Benzoyl-piperidine derivative 2 DMFKX1M N. A. N. A. Patented [29]
Diarylamine and arylheteroarylamine pyrazole derivative 1 DMXFNOD N. A. N. A. Patented [29]
Diarylamine and arylheteroarylamine pyrazole derivative 2 DM6NR9Y N. A. N. A. Patented [29]
Diarylamine and arylheteroarylamine pyrazole derivative 3 DMLZ1UB N. A. N. A. Patented [29]
L-piperazino-3-phenyl-indane derivative 1 DM1STAD N. A. N. A. Patented [29]
Piperazine derivative 3 DM8MZR6 N. A. N. A. Patented [29]
Piperazine derivative 4 DM2XGNY N. A. N. A. Patented [29]
PMID26609882-Compound-34 DMBYTSI N. A. N. A. Patented [29]
PMID26609882-Compound-35 DM8OLYQ N. A. N. A. Patented [29]
PMID26609882-Compound-36 DMFT3RM N. A. N. A. Patented [29]
PMID30124346-Compound-13TABLE4 DMHTJVA Attention deficit hyperactivity disorder 6A05.Z Patented [30]
PMID30124346-Compound-34TABLE4 DM2G3VE Attention deficit hyperactivity disorder 6A05.Z Patented [30]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [30]
Pyrazole derivative 67 DMNZUHX N. A. N. A. Patented [29]
Pyrazole derivative 68 DMVY0JT N. A. N. A. Patented [29]
Pyrazole derivative 69 DMKCJE1 N. A. N. A. Patented [29]
Pyrazole derivative 70 DMR6VIG N. A. N. A. Patented [29]
Pyrazole derivative 71 DMSNY3W N. A. N. A. Patented [29]
Pyrazole derivative 72 DMWFTCN N. A. N. A. Patented [29]
Pyrazole derivative 73 DMFARIK N. A. N. A. Patented [29]
Pyrazole derivative 74 DM70QPF N. A. N. A. Patented [29]
Pyrazole derivative 75 DMAB2EN N. A. N. A. Patented [29]
Pyrimidine derivative 23 DM5MLQU N. A. N. A. Patented [29]
Pyrimidine derivative 24 DMOQ726 N. A. N. A. Patented [29]
Pyrimidine derivative 25 DM51MFS N. A. N. A. Patented [29]
Pyrimidine derivative 26 DM90WKN N. A. N. A. Patented [29]
Pyrimidine derivative 27 DMIQSDW N. A. N. A. Patented [29]
Pyrimidine derivative 28 DM1D2AS N. A. N. A. Patented [29]
Pyrimidine derivative 29 DMVOYJ8 N. A. N. A. Patented [29]
------------------------------------------------------------------------------------
⏷ Show the Full List of 34 Patented Agent(s)
28 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
LYSERGIC ACID DIETHYLAMIDE DMACMLO Addictive disorder 6C50-6C5Z Withdrawn from market [31]
Deramciclane DM8DUZT Anxiety disorder 6B00-6B0Z Discontinued in Phase 3 [32]
Iferanserin-Ventrus DMDEL2W Hemorrhoids DB60 Discontinued in Phase 3 [33]
MDL-11939 DMUR3VP Anxiety disorder 6B00-6B0Z Discontinued in Phase 3 [34]
Ritanserin DM0X36Y Anxiety disorder 6B00-6B0Z Discontinued in Phase 3 [35]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [36]
Adatanserin DMMKFUP Mood disorder 6A60-6E23 Discontinued in Phase 2 [37]
AMESERGIDE DMRY9V8 Mood disorder 6A60-6E23 Discontinued in Phase 2 [38]
FCE-22716 DMT2Z1L Hypertension BA00-BA04 Discontinued in Phase 2 [39]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [40]
SERAZAPINE HYDROCHLORIDE DM75ZO0 Anxiety disorder 6B00-6B0Z Discontinued in Phase 2 [41]
SERGOLEXOLE MALEATE DM9KB8A Migraine 8A80 Discontinued in Phase 2 [42]
SL65.0472 DMU5RKC Cardiovascular disease BA00-BE2Z Discontinued in Phase 2 [43]
YM-992 DM845NM Depression 6A70-6A7Z Discontinued in Phase 2 [44]
AM-831 DMO7920 Schizophrenia 6A20 Discontinued in Phase 1 [45]
DUP-734 DMI5EPB Psychotic disorder 6A20-6A25 Discontinued in Phase 1 [46]
A-80426 DMBC3DG N. A. N. A. Terminated [47]
AMPEROZIDE DMDAMBW Alcohol dependence 6C40.2 Terminated [48]
DV-7028 DMKNJM7 Cardiovascular disease BA00-BE2Z Terminated [49]
Fananserin DME694O Schizophrenia 6A20 Terminated [50]
GMC-283 DMT1RH6 Schizophrenia 6A20 Terminated [10]
ICI-169369 DMQ0IOF Anxiety disorder 6B00-6B0Z Terminated [51]
LY53857 DMY71LJ N. A. N. A. Terminated [52]
MDL-28161 DM8ZDU2 N. A. N. A. Terminated [34]
R-102444 DM46YHG Pancreatitis DC31-DC34 Terminated [53]
Ro-60-0175 DMZSQU8 N. A. N. A. Terminated [54]
RP-68303 DM0BEM3 N. A. N. A. Terminated [55]
ZD-3638 DM6M9GC Schizophrenia 6A20 Terminated [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 28 Discontinued Drug(s)
1 Preclinical Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Org-23366 DMHQUM2 Schizophrenia 6A20 Preclinical [10]
------------------------------------------------------------------------------------
219 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
(+/-)-nantenine DM0L3GE Discovery agent N.A. Investigative [56]
(1-Phenethyl-piperidin-4-yl)-phenyl-methanone DMXY9R5 Discovery agent N.A. Investigative [9]
(2-Indol-1-yl-ethyl)-dimethyl-amine DM24E08 Discovery agent N.A. Investigative [57]
(2S)-1-(1H-furo[2,3-g]indazol-1-yl)propan-2-amine DMIS39C Discovery agent N.A. Investigative [54]
(2S)-1-(5-fluoro-1H-indazol-1-yl)propan-2-amine DMW4ARM Discovery agent N.A. Investigative [54]
(2S)-1-(6-fluoro-1H-indazol-1-yl)propan-2-amine DM31SNW Discovery agent N.A. Investigative [54]
(2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine DMYALON Discovery agent N.A. Investigative [58]
(E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine DMTJI4F Discovery agent N.A. Investigative [59]
(E)-2-(4-fluorostyryl)-5-(phenylsulfonyl)pyridine DM7P5VM Discovery agent N.A. Investigative [59]
(R)-(+)-(4,5,6-trimethoxyindan-1-yl)methanamine DM9DBHU Discovery agent N.A. Investigative [31]
(R)-(-)-11-hydroxy-N-n-propylnoraporphine DMKB621 Discovery agent N.A. Investigative [60]
(R)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine DMDC297 Discovery agent N.A. Investigative [61]
(R)-3-(4-propylmorpholin-2-yl)phenol DMC73DY Discovery agent N.A. Investigative [62]
(R,S)-1-(5-bromo-1H-indol-1-yl)propan-2-amine DMKZ4C6 Discovery agent N.A. Investigative [63]
(R,S)-1-(5-chloro-1H-indol-1-yl)propan-2-amine DMTZDAJ Discovery agent N.A. Investigative [63]
(R,S)-1-(5-fluoro-1H-indol-1-yl)propan-2-amine DMAU1M5 Discovery agent N.A. Investigative [63]
(R,S)-1-(5-methyl-1H-indol-1-yl)propan-2-amine DMS2DI9 Discovery agent N.A. Investigative [63]
(R,S)-1-(6-fluoro-1H-indol-1-yl)propan-2-amine DM0YELX Discovery agent N.A. Investigative [63]
(S)-(-)-(4,5,6-trimethoxyindan-1-yl)methanamine DMUNQY7 Discovery agent N.A. Investigative [31]
(S)-1-(5,6-difluoro-1H-indol-1-yl)propan-2-amine DMEIB8F Discovery agent N.A. Investigative [63]
1,2,3,4-Tetrahydro-naphthalen-2-ylamine DMP4DLV Discovery agent N.A. Investigative [64]
1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole DM3JGVF Discovery agent N.A. Investigative [57]
1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane DMDFU6S Discovery agent N.A. Investigative [65]
1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane DMNLUKS Discovery agent N.A. Investigative [65]
1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane DM0GRMD Discovery agent N.A. Investigative [65]
1,6-bis(4-m-tolylpiperazin-1-yl)hexane DM5Z6XG Discovery agent N.A. Investigative [65]
1,6-bis(4-phenylpiperazin-1-yl)hexane DMD3EUI Discovery agent N.A. Investigative [65]
1-((R)-2-aminopropyl)-1H-indazol-6-ol DM74R0E Discovery agent N.A. Investigative [58]
1-((S)-2-aminopropyl)-1H-indazol-6-ol DMU83KP Discovery agent N.A. Investigative [58]
1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol DMRFJNC Discovery agent N.A. Investigative [58]
1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol DM76JVB Discovery agent N.A. Investigative [58]
1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol DMR2SXL Discovery agent N.A. Investigative [58]
1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol DM8MNZG Discovery agent N.A. Investigative [58]
1-(10-Bromoanthracen-9-yl)-2-aminopropane DM2AEO0 Discovery agent N.A. Investigative [66]
1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine DM31CVR Discovery agent N.A. Investigative [67]
1-(2,5-Dimethoxy-phenyl)-piperazine DMNETHQ Discovery agent N.A. Investigative [67]
1-(2,5-dimethoxyphenyl)propan-2-amine DM043N8 Discovery agent N.A. Investigative [66]
1-(2,6-dimethoxy-4-methylphenyl)propan-2-amine DMV0C6F Discovery agent N.A. Investigative [66]
1-(2-aminoethyl)-1H-indazol-6-ol DMKWO6A Discovery agent N.A. Investigative [58]
1-(2-Methoxy-phenyl)-4-propyl-piperazine DMCADRI Discovery agent N.A. Investigative [68]
1-(2-Methoxy-phenyl)-piperazine DM3M4RA Discovery agent N.A. Investigative [67]
1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine DMX5N3V Discovery agent N.A. Investigative [69]
1-(3-(phenylthio)propyl)-4-m-tolylpiperazine DMXUNMW Discovery agent N.A. Investigative [70]
1-(4-Bromo-2,5-difluorophenyl)-2-aminopropane DMMLCSG Discovery agent N.A. Investigative [66]
1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine DMCH6R1 Discovery agent N.A. Investigative [67]
1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine DMIYLXU Discovery agent N.A. Investigative [66]
1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol DMO7NXE Discovery agent N.A. Investigative [71]
1-Butyl-4-(2-methoxy-phenyl)-piperazine DM6QULO Discovery agent N.A. Investigative [68]
1-Ethyl-4-(2-methoxy-phenyl)-piperazine DMGKP9Y Discovery agent N.A. Investigative [68]
1-methoxy-9-aminomethyl-9,10-dihydroanthracene DMAUZHJ Discovery agent N.A. Investigative [72]
1-Methyl-1,3-dihydro-indol-2-one DMMX7V8 Discovery agent N.A. Investigative [73]
1-Naphthalen-2-yl-piperazine DMJK0MF Discovery agent N.A. Investigative [64]
1-naphthylpiperazine DM6BIWK Discovery agent N.A. Investigative [64]
1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine DMOCAUL Discovery agent N.A. Investigative [74]
11-Butyryloxy-N-n-propylnoraporphine DMH5QEA Discovery agent N.A. Investigative [60]
11-Heptanoyloxy-N-n-propylnoraporphine DMX4I9D Discovery agent N.A. Investigative [60]
11-Hexanoyloxy-N-n-propylnoraporphine DMRYV9E Discovery agent N.A. Investigative [60]
11-Propionyloxy-N-n-propylnoraporphine DM62FEH Discovery agent N.A. Investigative [60]
11-valeryloxynoraporphine DMM91WE Discovery agent N.A. Investigative [60]
2,2-Diphenyl-ethylamine DMTBAUG Discovery agent N.A. Investigative [75]
2,5-dimethoxy-4-bromophenethylamine DM50ZQP Discovery agent N.A. Investigative [76]
2-(1H-indol-3-yl)-N,N-dimethylethanamine DMR9Q4Y Discovery agent N.A. Investigative [77]
2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol DMZNRFG Discovery agent N.A. Investigative [78]
2-(2-Methoxy-phenyl)-1-methyl-ethylamine DMDI98B Discovery agent N.A. Investigative [78]
2-(3,5-dimethoxy-4-phenethoxyphenyl)ethanamine DMIEB8R Discovery agent N.A. Investigative [66]
2-(3-Methoxy-phenyl)-1-methyl-ethylamine DM4C9H2 Discovery agent N.A. Investigative [78]
2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine DM79JVK Discovery agent N.A. Investigative [78]
2-(4-Bromo-phenyl)-1-methyl-ethylamine DMB49UP Discovery agent N.A. Investigative [78]
2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine DMDHFU9 Discovery agent N.A. Investigative [79]
2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine DM1O0JD Discovery agent N.A. Investigative [58]
2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine DMRW475 Discovery agent N.A. Investigative [80]
2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline DML6HSE Discovery agent N.A. Investigative [81]
2-methoxy-9-aminomethyl-9,10-dihydroanthracene DMXCAKO Discovery agent N.A. Investigative [72]
2-Phenyl-3-(2-piperidin-1-yl-ethyl)-1H-indole DM5YC2K Discovery agent N.A. Investigative [82]
2-Phenyl-3-piperidin-4-yl-1H-indole DMEXZQ5 Discovery agent N.A. Investigative [82]
2-Piperazin-1-yl-phenol DMQT9OK Discovery agent N.A. Investigative [67]
3-(1-Benzyl-piperidin-4-yl)-2-phenyl-1H-indole DMWP0VK Discovery agent N.A. Investigative [82]
3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole DM6R5HU Discovery agent N.A. Investigative [82]
3-(1-Phenethyl-piperidin-4-yl)-2-phenyl-1H-indole DM8TH2N Discovery agent N.A. Investigative [82]
3-(2-Amino-propyl)-1H-indol-5-ol DMQPNUM Discovery agent N.A. Investigative [58]
3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol DMKYZGD Discovery agent N.A. Investigative [71]
3-(2-Dimethylamino-ethyl)-1H-indol-6-ol DM32MIE Discovery agent N.A. Investigative [71]
3-(2-Dimethylamino-ethyl)-2-methyl-1H-indol-4-ol DM9BTLC Discovery agent N.A. Investigative [71]
3-(2-Dimethylamino-propyl)-1H-indol-4-ol DMMJP9D Discovery agent N.A. Investigative [71]
3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol DM7VJPX Discovery agent N.A. Investigative [71]
3-(3-Dimethylamino-propyl)-1H-indol-4-ol DM0O2ZB Discovery agent N.A. Investigative [71]
3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one DMKGIQ1 Discovery agent N.A. Investigative [67]
3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol DMDOIJM Discovery agent N.A. Investigative [71]
3-Dimethylaminomethyl-1H-indol-4-ol DMSJUOH Discovery agent N.A. Investigative [71]
3-methoxy-9-aminomethyl-9,10-dihydroanthracene DMO2N56 Discovery agent N.A. Investigative [72]
3-Naphthalen-1-yl-1-propyl-pyrrolidine DMNZI9R Discovery agent N.A. Investigative [74]
3-Naphthalen-1-yl-pyrrolidine DMCW7F5 Discovery agent N.A. Investigative [74]
4,4-Diphenylbutan-1-amine DMQ0TBX Discovery agent N.A. Investigative [80]
4-(10H-Anthracen-9-ylidene)-1-methyl-piperidine DM1SP36 Discovery agent N.A. Investigative [75]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [83]
4-(4-Fluoro-benzyl)-piperidine hydrochloride DM4NEOU Discovery agent N.A. Investigative [34]
4-Benzyl-1-methyl-piperidine hydrochloride DMQKCGI Discovery agent N.A. Investigative [34]
4-methoxy-9-aminomethyl-9,10-dihydroanthracene DM54A3W Discovery agent N.A. Investigative [72]
5,6-dichloro-3,4-dihydroquinazolin-2-amine DMN1S35 Discovery agent N.A. Investigative [84]
5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMMI4H3 Discovery agent N.A. Investigative [85]
5-chloro-3,4-dihydroquinazolin-2-amine DMKEFJ0 Discovery agent N.A. Investigative [84]
5-chloro-N-(pyridin-3-yl)indoline-1-carboxamide DMZ5MDY Discovery agent N.A. Investigative [63]
5-CT DM260KD Discovery agent N.A. Investigative [6]
5-MEO-DMT DMG0EL7 Discovery agent N.A. Investigative [58]
5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMNRSYA Discovery agent N.A. Investigative [85]
5-Methoxy-4,9-dihydro-3H-beta-carboline DMBOMZE Discovery agent N.A. Investigative [85]
5-METHOXYTRYPTAMINE DMARCKD Discovery agent N.A. Investigative [16]
6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine DM592FB Discovery agent N.A. Investigative [86]
6-bromoaplysinopsin DMQGB70 Discovery agent N.A. Investigative [87]
6-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole DMW6320 Discovery agent N.A. Investigative [57]
6-chloro-N-(pyridin-3-yl)indoline-1-carboxamide DMUY9TF Discovery agent N.A. Investigative [63]
6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMSA367 Discovery agent N.A. Investigative [85]
7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine DMIMLUO Discovery agent N.A. Investigative [86]
7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine DMVZA27 Discovery agent N.A. Investigative [86]
7-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole DMP5JF8 Discovery agent N.A. Investigative [57]
7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMQ1BE8 Discovery agent N.A. Investigative [85]
8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMALRU4 Discovery agent N.A. Investigative [85]
8-Bromo-4,9-dihydro-3H-beta-carboline DM4V5RU Discovery agent N.A. Investigative [85]
8-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole DMFW6Q0 Discovery agent N.A. Investigative [57]
8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMHE7J5 Discovery agent N.A. Investigative [85]
8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline DMQIFZC Discovery agent N.A. Investigative [64]
8-Methoxy-2-piperazin-1-yl-quinoline DMNWC29 Discovery agent N.A. Investigative [64]
8-Methoxy-4,9-dihydro-3H-beta-carboline DM8MBSN Discovery agent N.A. Investigative [85]
9-(2-aminoethyl)-9,10-dihydroanthracene DM4Y9U3 Discovery agent N.A. Investigative [80]
9-(2-aminopropyl)-9,10-dihydroanthracene DMND39P Discovery agent N.A. Investigative [80]
9-(Aminomethyl)-9,10-dihydroanthracene DM6QDNH Discovery agent N.A. Investigative [75]
9-(N-benzylaminomethyl)-9,10-dihydroanthracene DMA2RCD Discovery agent N.A. Investigative [88]
9-OH-risperidone DMGORXQ Discovery agent N.A. Investigative [89]
A-987306 DMU34BK Discovery agent N.A. Investigative [90]
ACP-106 DMBVHLT Central nervous system disease 8A04-8D87 Investigative [13]
AL-37350A DMRJ2GK Discovery agent N.A. Investigative [91]
alpha-methyl-5-HT DMCAYXF Discovery agent N.A. Investigative [92]
ALTANSERIN DMBGAWI Discovery agent N.A. Investigative [93]
Aplysinopsin DMUPL3J Discovery agent N.A. Investigative [63]
BARETTIN DMU3D2O Discovery agent N.A. Investigative [94]
BRL-15572 DMM61Y2 Discovery agent N.A. Investigative [95]
Brolamfetamine DMC4PF0 Discovery agent N.A. Investigative [96]
bufotenine DMD1SY9 Discovery agent N.A. Investigative [97]
BW723C86 DME15JU Discovery agent N.A. Investigative [6]
C-(5-bromo-4,7-dimethoxyindan-1-yl)methylamine DM0VKFO Discovery agent N.A. Investigative [76]
C-(5H-Dibenzo[a,d]cyclohepten-5-yl)-methylamine DMDHVY0 Discovery agent N.A. Investigative [75]
C-(9H-Thioxanthen-9-yl)-methylamine DMDMA4Z Discovery agent N.A. Investigative [75]
C-(9H-Xanthen-9-yl)-methylamine DMN5YOR Discovery agent N.A. Investigative [75]
CHLOROPHENYLPIPERAZINE DMOA8L2 Discovery agent N.A. Investigative [98]
CINANSERIN DM6TJFU Discovery agent N.A. Investigative [16]
cyamemazine DMZ6YPV Discovery agent N.A. Investigative [99]
DOM DM53KZX Discovery agent N.A. Investigative [66]
EGIS-7625 DMLK4X5 Discovery agent N.A. Investigative [100]
EPLIVANSERIN MESILATE DMDOR0L Discovery agent N.A. Investigative [101]
Etisulergine DMKH8TC Discovery agent N.A. Investigative [102]
FLUANISONE DMQSDM7 Discovery agent N.A. Investigative [103]
ISOCLOZAPINE DM52CPU Discovery agent N.A. Investigative [104]
LP-12 DM8ZR17 Discovery agent N.A. Investigative [105]
LP-44 DM0C3SF Discovery agent N.A. Investigative [105]
LY063518 DMNB82L Discovery agent N.A. Investigative [106]
LY108742 DMYNCQR Discovery agent N.A. Investigative [107]
LY215840 DM5RG7J Discovery agent N.A. Investigative [107]
LY314228 DMWAHYX Discovery agent N.A. Investigative [106]
LY320954 DM3DOI7 Discovery agent N.A. Investigative [106]
LY433222 DMP8OXG Depression 6A70-6A7Z Investigative [44]
LY86057 DM5TYMG Discovery agent N.A. Investigative [107]
m-chlorophenylpiperazine DMM1J2D Discovery agent N.A. Investigative [108]
MESCALINE DMYVUCE Discovery agent N.A. Investigative [66]
METHYLENEDIOXYMETHAMPHETAMINE DMYVU47 Discovery agent N.A. Investigative [109]
MMDA DMUWVGP Discovery agent N.A. Investigative [110]
MPDT DMYX31S Discovery agent N.A. Investigative [111]
N,N-dimethyl-2,2-diphenylethanamine DMJDQGR Discovery agent N.A. Investigative [80]
N,N-Dimethyl-3,3-diphenylpropan-1-amine DMIP5K7 Discovery agent N.A. Investigative [80]
N,N-dimethyl-4,4-diphenylbutan-1-amine DMX9U7S Discovery agent N.A. Investigative [80]
N-(1-(1-phenylethyl)piperidin-4-yl)-1-naphthamide DMJWTH9 Discovery agent N.A. Investigative [112]
N-(1-(1-phenylethyl)piperidin-4-yl)-2-naphthamide DMMCGL3 Discovery agent N.A. Investigative [112]
N-(1-(3-bromobenzyl)piperidin-4-yl)-1-naphthamide DMGYLC1 Discovery agent N.A. Investigative [113]
N-(1-(3-bromobenzyl)piperidin-4-yl)-2-naphthamide DMRQKYC Discovery agent N.A. Investigative [113]
N-(1-(4-bromobenzyl)piperidin-4-yl)-2-naphthamide DMS9RDW Discovery agent N.A. Investigative [113]
N-(1-(4-nitrobenzyl)piperidin-4-yl)-2-naphthamide DMAP4R8 Discovery agent N.A. Investigative [113]
N-(1-(4-phenylbutyl)piperidin-4-yl)-1-naphthamide DMQSLJI Discovery agent N.A. Investigative [112]
N-(1-(4-phenylbutyl)piperidin-4-yl)-2-naphthamide DMZ84JH Discovery agent N.A. Investigative [112]
N-(1-benzylpiperidine-4-yl)-2-naphthamide DMUQ6P4 Discovery agent N.A. Investigative [113]
N-(1-phenethylpiperidin-4-yl)-1-naphthamide DMU9YF6 Discovery agent N.A. Investigative [112]
N-(1-phenethylpiperidin-4-yl)-2-naphthamide DM9QA7Z Discovery agent N.A. Investigative [112]
N-1-isopropyl-5-MeOT DM5LC3D Discovery agent N.A. Investigative [107]
N-1-isopropyltryptamine DM25NLH Discovery agent N.A. Investigative [107]
N-3'-ethylaplysinopsin DMWZTKD Discovery agent N.A. Investigative [87]
N-methyl-3,3-diphenylpropan-1-amine DM8IHQP Discovery agent N.A. Investigative [80]
N-methyl-4,4-diphenylbutan-1-amine DMO3PNF Discovery agent N.A. Investigative [80]
norfluoxetine DMKNUP3 Discovery agent N.A. Investigative [114]
Org 12962 DM8JUBG Discovery agent N.A. Investigative [6]
PG-01037 DM2TP4Q Discovery agent N.A. Investigative [115]
PHENETHYLAMINE DMX0G4F Discovery agent N.A. Investigative [75]
PHENYLPIPERAZINE DMWAK1R Discovery agent N.A. Investigative [64]
PSILOCIN DMPDO49 Discovery agent N.A. Investigative [66]
QUIPAZINE DMPY6IG Discovery agent N.A. Investigative [116]
Racemic DOI DM39FSQ Discovery agent N.A. Investigative [66]
Racemic DOTFM DMNLCUH Discovery agent N.A. Investigative [66]
SB 215505 DMCM4LT Discovery agent N.A. Investigative [117]
SB 216641 DMB3R4Z Discovery agent N.A. Investigative [95]
SB 221284 DM8DVY2 Discovery agent N.A. Investigative [6]
SB 228357 DMKA8R4 Discovery agent N.A. Investigative [118]
SB 242084 DMISBDC Discovery agent N.A. Investigative [119]
SB-271046 DM5VJAF Discovery agent N.A. Investigative [120]
SEL-73 DMFKE6C Psychiatric disorder 6E8Z Investigative [13]
SEROTONIN DMOFCRY Discovery agent N.A. Investigative [116]
spiramide DM5KNMD Discovery agent N.A. Investigative [6]
TFMPP DMAC8TP Discovery agent N.A. Investigative [6]
TRYPTOLINE DMV19K7 Discovery agent N.A. Investigative [85]
VER-2692 DM5WAM8 Discovery agent N.A. Investigative [121]
VER-3323 DM7O2K1 Discovery agent N.A. Investigative [122]
VER-5384 DMC2EO9 Discovery agent N.A. Investigative [122]
VER-5593 DMZ2V0A Discovery agent N.A. Investigative [122]
Very low dose (VLD) cyclobenzaprine DMUHEJ3 Fibromyalgia MG30.01 Investigative [13]
WAY-208466 DM9K2LU Discovery agent N.A. Investigative [123]
YM-348 DM38F9T Discovery agent N.A. Investigative [86]
[11C]volinanserin DMCQTYW Discovery agent N.A. Investigative [124]
[125I]DOI DMQUY08 Discovery agent N.A. Investigative [125]
[18F]altanserin DM65BDN Discovery agent N.A. Investigative [126]
[2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine DMDIH96 Discovery agent N.A. Investigative [71]
[2-(6-Methoxy-indol-1-yl)-ethyl]-dimethyl-amine DMHPBQC Discovery agent N.A. Investigative [57]
[3H]N-methylspiperone DM5176Y Discovery agent N.A. Investigative [92]
[3H]spiperone DMWHEV8 Discovery agent N.A. Investigative [127]
------------------------------------------------------------------------------------
⏷ Show the Full List of 219 Investigative Drug(s)
Molecule Interaction Atlas

References

1 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
2 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
3 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
6 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
7 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
8 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
9 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
10 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
11 Clinical pipeline report, company report or official report of Intra-Cellular Therapies, Inc.
12 Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther. 2001 Apr;297(1):357-63.
13 Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59.
14 SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
15 Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
16 Central serotonin receptors as targets for drug research. J Med Chem. 1987 Jan;30(1):1-12.
17 Clinical pipeline report, company report or official report of Lundbeck.
18 Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011; 5: 667-677.
19 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
20 Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia.J Pharmacol Exp Ther.2010 Jan;332(1):281-90.
21 The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091.
22 5-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem. 2008;8(11):969-76.
23 Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
24 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602). J Med Chem. 1998 Dec 31;41(27):5402-9.
25 Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
26 Bi-directional modulation of BNST neurons by 5-HT: Molecular expression and functional properties of excitatory 5-HT receptor subtypes. Neuroscience. 2009 December 29; 164(4): 1776-1793.
27 Clinical pipeline report, company report or official report of Arena Pharmaceuticals.
28 Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin Pharmacol Ther. 2007 Feb;81(2):252-8.
29 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
30 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
31 C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. J Med Chem. 2006 Jul 13;49(14):4269-74.
32 Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation. Psychopharmacology (Berl). 1998 Mar;136(2):99-104.
33 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 6).
34 Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem. 1992 Dec 25;35(26):4903-10.
35 Characterization of contractile 5-hydroxytryptamine receptor subtypes in the in situ autoperfused kidney in the anaesthetized rat. Eur J Pharmacol. 2008 Sep 11;592(1-3):133-7.
36 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
37 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
38 Effects of the serotonin antagonist amesergide on reproduction in female rats. Reprod Toxicol. 1993 Nov-Dec;7(6):607-12.
39 Mechanism of the antihypertensive effect of FCE 22716, a new ergoline derivative, in the spontaneously hypertensive rat. Pharmacology. 1989;38(2):78-92.
40 A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
41 Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder. Biol Psychiatry. 1993 Jul 1-15;34(1-2):41-4.
42 5-Hydroxytryptamine2 receptor antagonist activity of the acid metabolite (1-isopropyl dihydrolysergic acid) of the ergoline ester, sergolexole (LY281067). J Pharmacol Exp Ther. 1989 Dec;251(3):1006-11.
43 Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.Thromb Haemost.2001 Mar;85(3):521-8.
44 Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23.
45 Clinical pipeline report, company report or official report of Avarx.
46 Piperidinyltetralin sigma ligands. J Med Chem. 1994 Feb 4;37(3):364-70.
47 Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
48 Action of the 5-HT2A antagonist amperozide on alcohol-induced poikilothermia in rats. Pharmacol Biochem Behav. 1998 Jan;59(1):91-5.
49 Vascular and cardiac effects of DV-7028, a selective, 5-HT2-receptor antagonist in rats. J Cardiovasc Pharmacol. 1998 Aug;32(2):266-73.
50 Autoradiographic studies of RP 62203, a potent 5-HT2 receptor antagonist. Pharmacological characterization of [3H]RP 62203 binding in the rat brain. Eur J Pharmacol. 1993 Mar 16;233(1):37-45.
51 Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects.Drugs Today (Barc).2010 Mar;46(3):183-93.
52 The 5-hydroxytryptamine2A receptor is involved in (+)-norfenfluramine-induced arterial contraction and blood pressure increase in deoxycorticostero... J Pharmacol Exp Ther. 2007 May;321(2):485-91.
53 Effects of R-102444 and its active metabolite R-96544, selective 5-HT2A receptor antagonists, on experimental acute and chronic pancreatitis: Additional evidence for possible involvement of 5-HT2A receptors in the development of experimental pancreatitis.Eur J Pharmacol.2005 Oct 3;521(1-3):156-63.
54 Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82.
55 New indole derivatives as potent and selective serotonin uptake inhibitors. J Med Chem. 1993 Apr 30;36(9):1194-202.
56 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
57 Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2002 Jan 21;12(2):155-8.
58 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
59 2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2643-8.
60 N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8.
61 Novel benzodifuran analogs as potent 5-HT2A receptor agonists with ocular hypotensive activity. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2998-3002.
62 Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6691-6.
63 Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92.
64 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80.
65 Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
66 The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9.
67 Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4.
68 Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new ... J Med Chem. 1994 Aug 19;37(17):2754-60.
69 The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66.
70 Synthesis and QSAR studies on hypotensive 1-[3-(4-substituted phenylthio) propyl]-4-(substituted phenyl) piperazines. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1708-12.
71 SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.
72 Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT(2A) receptor. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5268-71.
73 Influence of the terminal amide fragment geometry in some 3-arylideneindolin-2(1H)-ones on their 5-HT1A/5-HT2A receptor activity. Bioorg Med Chem Lett. 2001 May 7;11(9):1229-31.
74 Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
75 Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6.
76 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agoni... J Med Chem. 2006 Sep 21;49(19):5794-803.
77 Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994 Feb;51(2):85-97.
78 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9.
79 4-(3-furyl)-2-(4-methylpiperazino)pyrimidines: Potent 5-HT2A receptor antagonists, Bioorg. Med. Chem. Lett. 7(13):1635-1638 (1997).
80 Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
81 Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71.
82 3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indoles as bioavailable h5-HT2A antagonists. Bioorg Med Chem Lett. 2000 Dec 18;10(24):2701-3.
83 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
84 Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
85 Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5.
86 Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20.
87 New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. J Nat Prod. 2002 Apr;65(4):476-80.
88 9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites. Bioorg Med Chem Lett. 2010 Feb 1;20(3):935-8.
89 Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.
90 cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
91 A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole. J Med Chem. 2003 Sep 11;46(19):4188-95.
92 Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol Pharmacol. 2000 Nov;58(5):877-86.
93 Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorg Med Chem. 2009 Apr 15;17(8):2989-3002.
94 Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4.
95 SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
96 'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. Bioorg Med Chem. 2008 Jun 1;16(11):6242-51.
97 Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. J Biol Chem. 1996 Jun 21;271(25):14672-5.
98 Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1128-33.
99 Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem Pharmacol. 2003 Feb 1;65(3):435-40.
100 Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist. Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):427-34.
101 Role of 5-HT2A receptor antagonists in the treatment of insomnia
102 Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-... J Med Chem. 1985 Oct;28(10):1540-2.
103 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. J Med Chem. 1987 Nov;30(11):2099-104.
104 Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. J Med Chem. 1997 Dec 5;40(25):4146-53.
105 Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21.
106 A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines. Life Sci. 1996;59(15):1259-68.
107 Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol. 1994 Feb;45(2):277-86.
108 Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jan;359(1):1-6.
109 The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5.
110 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
111 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
112 Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the ... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1565-9.
113 Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the a... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1570-4.
114 Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41.
115 Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46.
116 Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characteri... J Med Chem. 2009 Nov 12;52(21):6946-50.
117 Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol. 1999 Feb;126(3):572-4.
118 Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem. 2000 Mar 23;43(6):1123-34.
119 SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 1997 Apr-May;36(4-5):609-20.
120 Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.
121 Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):677-80.
122 Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.
123 Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63.
124 Autoradiographic localization of 5-HT(2A) receptors in the human brain using [(3)H]M100907 and [(11)C]M100907. Synapse. 2000 Dec 15;38(4):421-31.
125 Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem. 2000 Nov 30;43(24):4701-10.
126 Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging. Psychiatry Res. 1996 Nov 25;68(1):11-22.
127 Activity of Parthenolide at 5HT2A receptors. J Nat Prod. 1997 Jun;60(6):651-3.